Lilly Takes Another Leap Into Gene Therapy With Jaguar

Co-leads $139m Fundraising

Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.

Jaguar
Jaguar eyes opportunities in gene therapy field • Source: Alamy

Eli Lilly and Company has made another move in bolstering its presence in genetic diseases by driving a $139m series B financing for Jaguar Gene Therapy and its pipeline that includes potential one-time treatments for type 1 diabetes and autism.

The Illinois-based company only came out of stealth mode at the end of February this year, led by key members...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies